Crypto stocks and TSLA. McKesson, Oracle among finalists to acquire Veradigm: report. Smith & Nephew investors may push for ...
It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions ...
We rate McKesson as a 'Strong Buy' with focus on GLP-1 meds, oncology network, and strong Q2 results driving future growth.
This growth is supported by the ongoing adoption of personal protective equipment (PPE) and infection control protocols in healthcare facilities across the region. Key Insights on the Medical Glove ...
It supplied drugs and other medical supplies to 34 Walgreens pharmacies in Baltimore. A former DEA agent, Ruth Carter, ...
Fintel reports that on November 7, 2024, Baird upgraded their outlook for McKesson (NYSE:MCK) from Neutral to Outperform. ...
McKesson's second-quarter fiscal 2025 results showcase growth in the U.S. Pharmaceutical segment. However, Medical Surgical ...
Steve Baxter, an analyst from Wells Fargo, maintained the Hold rating on McKesson (MCK – Research Report). The associated price target ...
McKesson (MCK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Allen Lutz ...
Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company ...